[1] Andrés Cerezo L, Mann H, Pecha O, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis[J]. Arthritis Res Ther, 2011, 13(4): R122
[2] Prevoo M L, Van’t Hof M A, Kuper H H, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis[J]. Arthritis Rheum, 1995, 38(1): 44
[3] Kopeé-M?誰drek M, Widuchowska M, Kucharz E J. Calprotectin in rheumatic diseases: a review[J]. Reumatologia, 2016, 54(6): 306
[4] Bae S C, Lee Y H. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis[J]. Postgrad Med, 2017, 129(5): 531
[5] Malemud C J. Myeloid-related protein activity in rheumatoid arthritis[J]. Int J Inflam, 2011 ,2011: 580295
[6] Pruenster M, Vogl T, Roth J, et al. S100A8/A9: from basic science to clinical application[J]. Pharmacol Ther, 2016, 167: 120
[7] Hammer H B, Odegard S, Fagerhol M K, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis[J]. Ann Rheum Dis, 2007, 66(8): 1093
[8] Choi I Y, Gerlag D M, Herenius M J, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis[J]. Ann Rheum Dis, 2015, 74(3): 499
[9] Hurnakova J, Hulejova H, Zavada J, et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study[J]. PLoS One, 2017, 12(8): e0183420
[10] Choi I Y, Gerlag D M, Holzinger D, et al. From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis[J]. PLoS One, 2014, 9(8): e106253